Anti-tumor necrosis factor (anti-TNF) medications are effective in controlling chronic inflammatory diseases, but information about pregnancy outcomes is still limited. Certolizumab pegol (CZP), a PEGylated, Fc-free anti-TNF approved for treatment of Crohn’s disease (CD) and/or rheumatic diseases (RD), has no active placental transfer. This project provides information on pregnancy exposure and outcomes in women receiving CZP.